Recovery from Bell’s palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report

Ahn, Hyunjun; Jung, Won-Ju; Lee, Sang Yeon; Lee, Kye-Ho

doi:10.12998/wjcc.v11.i12.2817

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another neurological condition with highly debilitating outcomes is the paralysis of the facial nerve, with Bell's palsy being a common mononeuropathy with persistent symptomatology. After a first case study suggesting the opportunity to treat Bell's palsy with adipose‐derived stem cells (Ahn et al., 2023 ), one pilot study sought to determine whether a 4‐week treatment with MSC‐EVs (injected into the area of the main trunk of the facial nerve on the affected side) was able to restore facial nerve function in seven patients with idiopathic facial paralysis, unable to return to normal upon diversified therapeutic approaches. No adverse effects were observed in the study and authors report a progression of independent motion of the affected eyelid, brow motion, and commissure for all the treated patients (study n.18, Table 1 ) (Dreschnack & Belshaku, 2023 ).…”

Section: Hyper‐inflammatory Conditionsmentioning

confidence: 99%

Extracellular vesicles as human therapeutics: A scoping review of the literature

Fusco,

De Rosa,

Spatocco

et al. 2024

J of Extracellular Vesicle

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are released by all cells and contribute to cell‐to‐cell communication. The capacity of EVs to target specific cells and to efficiently deliver a composite profile of functional molecules have led researchers around the world to hypothesize their potential as therapeutics. While studies of EV treatment in animal models are numerous, their actual clinical benefit in humans has more slowly started to be tested. In this scoping review, we searched PubMed and other databases up to 31 December 2023 and, starting from 13,567 records, we selected 40 pertinent published studies testing EVs as therapeutics in humans.The analysis of those 40 studies shows that they are all small pilot trials with a large heterogeneity in terms of administration route and target disease. Moreover, the absence of a placebo control in most of the studies, the predominant local application of EV formulations and the inconsistent administration dose metric still impede comparison across studies and firm conclusions about EV safety and efficacy. On the other hand, the recording of some promising outcomes strongly calls out for well‐designed larger studies to test EVs as an alternative approach to treat human diseases with no or few therapeutic options.

show abstract

Section: Hyper‐inflammatory Conditionsmentioning

confidence: 99%